Text Size

Pharmacokinetics of Dalteparin in Patients With Impaired Renal Function

This study has been completed.
Sponsor:
Collaborator:
Pfizer
Information provided by:
Luzerner Kantonsspital
ClinicalTrials.gov Identifier:
NCT00264693
First received: December 11, 2005
Last updated: January 25, 2010
Last verified: August 2009
History of Changes
  Purpose

Low molecular weight heparins (LMWH) have been shown to be at least as efficient and safe as unfractioned heparin (UFH) in prophylaxis and treatment of venous thromboembolic events and in therapy of acute cardiovascular diseases. LMWH are widely used as safe replacement of oral anticoagulation with vitamin K antagonists (VKA).

Due to their pharmacokinetic characteristics, LMWH tend to accumulate in patients with impaired renal function. Official guidelines recommend therefore to use LMWH controlled by Anti-Xa levels or to use UFH instead of LMWH to provide full therapeutic anticoagulation therapy in patients with severe renal insufficiency.

Although dosage recommendations have been proposed for enoxaparin in patients with renal impairment based on several studies, these data cannot be applied to other LMWH directly due to different pharmacokinetic properties of each drug.

The present study aims to clarify the pharmacokinetics of dalteparin in patients with renal insufficiency, especially addressing the question of accumulation after multiple doses and including patients with severe renal insufficiency and derive a safe and suitable concept for using dalteparin in patients with impaired renal function.


Condition Phase
Renal Insufficiency
 Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Pharmacokinetics of Dalteparin in Patients With Impaired Renal Function

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Luzerner Kantonsspital:

Enrollment: 96
Study Start Date: January 2006
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
P - A
Prophylactic Dosage, GFR >= 60 mL/min/1.73m^2
P - B
Prophylactic Dosage, GFR 30-59 mL/min/1.73m^2
P - C
Prophylactic Dosage, GFR < 30 mL/min/1.73m^2
P - CAPD
Prophylactic Dosage, CAPD
T - A
Therapeutic Dosage, GFR >= 60 mL/min/1.73m^2
T - B
Therapeutic Dosage, GFR 30-59 mL/min/1.73m^2
T - C
Therapeutic Dosage, GFR < 30 mL/min/1.73m^2
T - CAPD
Therapeutic Dosage, CAPD

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients of a medical and surcigal department with all levels of renal function who needs Dalteparin for prophylaxis or therapy.

Criteria

Inclusion Criteria:

  • Patient starting with dalteparin for prophylaxis OR therapy by order of the treating physician (after having evaluated clinical indication and contraindications).
  • Renal function normal OR impaired with or without dialysis therapy according to open study groups
  • Age >= 18 years
  • Written informed consent

Exclusion Criteria:

  • Pregnancy / Lactation
  • Dalteparin or other LMWH already in use for > 1 day, unless just in use during hemodialysis
  • Anti-Xa level before first application of dalteparin > 0.3 U / ml
  • Participation in another study
  • Anuria OR glomerular filtration rate < 10 ml/min without dialysis
  • Patient on intensive care unit (ICU)
  • Cardiovascular unstable patient or probable need for a quick stop of anticoagulation (e.g. emergency surgery)
  • Patient with a disease whose estimated life expectancy is < 28 days
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00264693

Locations
Switzerland
Kantonsspital Luzern
Luzern, LU, Switzerland, 6000
Sponsors and Collaborators
Luzerner Kantonsspital
Pfizer
Investigators
Principal Investigator: Pirmin Schmid, MD Luzerner Kantonsspital, Hematology
Study Director: Andreas G Fischer, MD Luzerner Kantonsspital, Nephrology
Study Chair: Walter A Wuillemin, MD, PhD Luzerner Kantonsspital, Hematology
  More Information

Additional Information:
Luzerner Kantonsspital, Hematology  This link exits the ClinicalTrials.gov site
Luzerner Kantonsspital, Nephrology  This link exits the ClinicalTrials.gov site
Pirmin Schmid  This link exits the ClinicalTrials.gov site

Publications:

Responsible Party: W.A. Wuillemin, MD PhD, Head, Division of Hematology and Hematology Central Laboratory, Kantonsspital Luzern, Luzern, Switzerland
ClinicalTrials.gov Identifier: NCT00264693     History of Changes
Other Study ID Numbers: LMWHplus 3, Ethikkommission Luzern 542, KSL 2006-1H
Study First Received: December 11, 2005
Last Updated: January 25, 2010
Health Authority: Switzerland: Swissmedic

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Dalteparin
Anticoagulants
Hematologic Agents
 Therapeutic Uses
Pharmacologic Actions
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents

ClinicalTrials.gov processed this record on May 16, 2013